

Table 1: Incidence and severity of toxicities

<b>Toxicities</b>	<b>VPA (n=100)</b>	<b>CBZ (n=100)</b>
<b>Neutropenia</b>	<b>9 (9%)</b>	<b>10 (10%)</b>
Neutrophils below $0.5 \times 10^9/L$	0	0
Neutrophils between $0.5-0.99 \times 10^9/L$	1	1
Neutrophils between $1.0-1.49 \times 10^9/L$	8	9
Appeared in the first six months of treatment	4 (44.4%)	4 (40%)
<b>Thrombocytopenia</b>	<b>8 (8%)</b>	<b>2 (2%)</b>
Platelets below $50 \times 10^9/L$	1	0
Platelets between $50-99 \times 10^9/L$	0	0
Platelets between $100-149 \times 10^9/L$	7	2
Appeared in the first six months of treatment	4 (50%)	0
<b>Anemia</b>	<b>3 (3%)</b>	<b>4 (4%)</b>
Appeared in the first six months of treatment	1 (33.3%)	4 (100%)
<b>Liver toxicity</b>	<b>4 (4%)</b>	<b>0</b>
SGOT/SGPT above 5 times ULN	1	0
SGOT/SGPT between 3-5 times ULN	3	0
SGOT/SGPT between 1-3 times ULN	26	19
Appeared in the first six months of treatment	2 (50%)	0
<b>Hyperammonemia</b>	26 (26%)	NE
Mean ammonia (mcmol/L) $\pm$ SD	64,2 $\pm$ 15,3	NE
Appeared in the first six months of treatment	10 (41.7%)	NE
<b>Hyponatremia</b>	NE	0
<b>At least one toxicity</b>	40	14
<b>More than one toxicity</b>	10	2
VPA: valproic acid; CBZ: carbamazepine; SGOT: serum glutamic oxaloacetic transaminase ; SGPT: serum glutamic pyruvic transaminase; ULN: upper limit of normal; -: not evaluated.		